Basic information Safety Related Supplier

ChemicalBook Product Catalog API Circulatory system drugs Antihypertensive drugs Cilazapril Monohydrate

1/1

Cilazapril Monohydrate NEW

$ 198.00 /25mg

Min. Order
Purity
Cas No92077-78-6
Supply Ability10g
Update time2024-11-19

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

1YR

United States

show more

Chemical Properties

Product Name	Cilazapril Monohydrate
CAS No	92077-78-6
EC-No
Min. Order
Purity
Supply Ability	10g
Release date	2024/11/19

Product Introduction

Bioactivity

Name	Cilazapril Monohydrate
Description	Cilazapril Monohydrate (Justor) is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.
In vitro	BML-190 has 50-fold selectivity for CB2 receptors over CB1 receptors. In HEK-293 cells stably expressing the human CB2 receptor, BML-190 potentiates the forskolin-stimulated accumulation of cAMP. BML-190 reduces the basal levels of inositol phosphate production in cells expressing the CB2 receptor. 10 μM of BML-190 decreases inositol phosphates accumulation by 38%. [1] BML-190 is an aminoalkylindole. BML-190 is found to yield at least 15 metabolic products. [2] BML-190 diminishes LPS-induced NO and IL-6 production in a concentration-dependent manner. BML-190 also inhibits LPS-induced PGE2 production and COX-2 induction. [3]
In vivo	Cilazapril (1 mg/kg, daily) tends to decrease and the higher dose (10 mg/kg, daily) significantly decreases systolic blood pressure (SBP) in subtotal nephrectomized rats. Cilazapril attenuates the further development of protein uria in a dose-dependent manner in subtotal nephrectomized rats. Cilazapril attenuates the increase in plasma fibrinogen concentration and serum albumin concentration in a dose-dependent manner. Cilazapril reduces serum MCP-1 concentration in the nephrectomized rats. Cilazapril decreases hepatic fibrinogen synthesis through the alleviation of the local inflammatory process and the improvement of hypoalbuminemia. [1] Cilazapril normalizes systolic arterial pressure to 121 mm Hg (SD) in the treated SHR-SP rats. Cilazapril decreases systolic arterial pressure to a nearly normal level and prevents hypertensive retinal vascular changes, probably by improving endothelial function. [2] Cilazapril results in a marked decrease in the Kd of the renal arginine vasopressin (AVP) receptor and an increase in the plasma AVP level in the spontaneously hypertensive rat. [3] Cilazapril exerts a rapid, complete, and persistent antihypertensive effect in the spontaneously hypertensive rats (SHR) in vivo but has no effect on SAP in the normotensive Sprague-Dawley rat. Cilazapril treatment depresses heart performance (28-35%) in SHR but has no effect in the Sprague-Dawley rats. [4] Cilazapril decreases blood pressure to control values and reduces HW:BW in hyperthyroid rats. [5]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	Ethanol : 81 mg/mL (186 mM) H2O : <1 mg/mL DMSO : 81 mg/mL (186 mM)
Keywords	Angiotensin-converting Enzyme (ACE) \| Cilazapril Monohydrate \| Inhibitor \| Ro 31-2848 Monohydrate \| Ro 31-2848 \| inhibit \| Cilazapril
Inhibitors Related	Tranilast \| Enalapril Maleate \| Azilsartan Methyl Ester \| Sacubitril/Valsartan \| Azilsartan \| Irbesartan \| Losartan \| Ramipril \| Captopril \| Valsartan Methyl Ester

show more

Company Profile Introduction

You may like

Recommended supplier

MSDS|CAS|CAS DataBase|Pricacy|Terms|About Us|New Products| Contact us|Computer Version
Chemical Book